---
schema_version: "secwatch.filing_event.v1"
accession: "0001576885-25-000091"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:33:04.043039+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Acumen reports Q2 2025 net loss $41M, cash $166.2M; Phase 2 Alzheimer's topline expected late 2026

## Summary
- Cash, equivalents, and marketable securities totaled $166.2M as of June 30, 2025, expected to fund operations into early 2027.
- Net loss for Q2 2025 was $41.0M compared to $20.5M in Q2 2024, driven by higher R&D expenses.
- Topline results from Phase 2 ALTITUDE-AD trial of sabirnetug for early Alzheimer's expected in late 2026.
- Announced collaboration with JCR Pharmaceuticals for Enhanced Brain Delivery therapy; non-clinical data expected early 2026.
- At AAIC 2025, presented data showing sabirnetug has 8,750-fold selectivity for toxic amyloid beta oligomers over monomers.

## SEC filing metadata
- accession: 0001576885-25-000091
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000157688525000091/0001576885-25-000091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000157688525000091/abos-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576885-25-000091
- JSON: https://secwatch.observer/filing/0001576885-25-000091.json
- Plain text: https://secwatch.observer/filing/0001576885-25-000091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.